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A B S T R A C T
The Aim of the study was to reveal if PET-CT analysis of primary and of secondary lung cancer could be related
to the onset of lipid peroxidation in cancer and in surrounding non-malignant lung tissue.
Methods: Nineteen patients with primary lung cancer and seventeen patients with pulmonary metastasis were
involved in the study. Their lungs were analyzed by PET-CT scanning before radical surgical removal of the
cancer. Specific immunohistochemistry for the major bioactive marker of lipid peroxidation, 4-hydroxynonenal
(HNE), was done for the malignant and surrounding non-malignant lung tissue using genuine monoclonal
antibody specific for the HNE-histidine adducts.
Results: Both the intensity of the PET-CT analysis and the HNE-immunohistochemistry were in correlation
with the size of the tumors analyzed, while primary lung carcinomas were larger than the metastatic tumors.
The intensity of the HNE-immunohistochemistry in the surrounding lung tissue was more pronounced in the
metastatic than in the primary tumors, but it was negatively correlated with the cancer volume determined by
PET-CT. The appearance of HNE was more pronounced in non-malignant surrounding tissue than in cancer or
stromal cells, both in case of primary and metastatic tumors.
Conclusions: Both PET-CT and HNE-immunohistochemistry reflect the size of the malignant tissue. However,
lipid peroxidation of non-malignant lung tissue in the vicinity of cancer is more pronounced in metastatic than
in primary malignancies and might represent the mechanism of defense against cancer, as was recently revealed
also in case of human liver cancer.
1. Introduction
The basic feature of a tumor cell is the metabolic switch from
oxidative phosphorylation to anaerobic glycolysis even under circum-
stances of normal oxygen saturation, a phenomenon known as the
Warburg effect [1]. Lactate dehydrogenase (LDHA) catalyzes the
conversion of pyruvate to lactate, and is considered the key enzyme
that regulates anaerobic metabolism, including the increased expres-
sion of the Glut-1 to Glut-4 transport proteins [2,3]. The mentioned
tumor cell feature is used in the diagnostic method of Positron
Emission Tomography and Computed Tomography (PET-CT) scan-
ning. Instead of glucose, the glucose analog 18-fluorodeoxyglucose
http://dx.doi.org/10.1016/j.redox.2017.01.005
Received 16 December 2016; Received in revised form 4 January 2017; Accepted 5 January 2017
⁎ Correspondence to: Rudjer Boskovic Institute, LabOS, Bijenička 54, HR-1000 Zagreb, Croatia.
E-mail address: zarkovic@irb.hr (N. Žarković).
Abbreviations: PET-CT, Positron Emission Tomography-Computed Tomography; 4-HNE, 4-hydroxynonenal; 18F-FDG, 18-fluorodeoxyglucose; SPN, solitary pulmonary nodule;
LDHA, Lactate dehydrogenase A; SUV, standardized uptake value; ROS, reactive oxygen species; RNS, reactive nitrogen species; RALBP1, Ral-binding protein1; Nrf2, nuclear factor
erythroid 2-related factor; Keap1, Kelch-like ECH-associated protein 1; TAM, tumor-associated macrophages; VEGF, vascular endothelial growth factor; NSCLC, non-small cell lung
cancer; VATS, video-assisted thoracoscopic surgery; GSH, glutathione; mAb, monoclonal antibodies; hydroxyl radical OH-, superoxide O2
-; N, nitrogen oxide; NO2, nitrogen dioxide;
H2O2, hydrogen peroxide; HOCl, hypochloric acid; O3, ozone; NADPH, nicotinamide adenine dinucleotide phosphate Nox oxidase; iNOS, inducible nitric oxide synthase; MMP, matrix
metalloproteinases
Redox Biology 11 (2017) 600–605
Available online 11 January 2017
2213-2317/ © 2017 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
MARK
(18F-FDG) is used. Cancer cells phosphorylate 18F-FDG by hexokinase
to FDG-6-phosphate, a compound which is not further metabolized but
accumulates in the cell. The intensity of 18F-FDG accumulation is
quantitatively expressed by standardized uptake value (SUVmax) [4–
6]. The metabolic activity of the tumor expressed as SUVmax is in
correlation with the intensity of anaerobic glycolysis of malignant cells
and the number of metabolically active cancer cells. In the majority of
clinical studies, a SUV of > 2.5 is considered the cut-off value
indicating a malignant etiology of the pulmonary nodule [7–12]
(Fig. 1).
Oxidative stress is defined as an imbalance in the cellular redox
reactivity towards oxidation, resulting in an increased production of
reactive oxygen species (ROS) and reactive nitrogen species (RNS).
Reactive oxygen and nitrogen species include various substances like
the oxygen free radicals superoxide (O2
-) and hydroxyl radical (OH-),
the nitrogen free radicals nitrogen oxide (NO) and nitrogen dioxide
(NO2), as well as molecules such as hydrogen peroxide (H2O2),
hypochloric acid (HOCl) and ozone (O3). Among ROS the most reactive
are free radicals, which contain an unpaired electron in their outer
shells [13,14]. ROS may lead to irreversible damage in macromolecules
such as DNA, proteins and lipids, where the occurrence of self-
catalyzed chain reaction of lipid peroxidation plays a particular role,
with the subsequent production of reactive aldehydes out of which 4-
hydroxynonenal (HNE) is of major interest due to its numerous
biological effects. Thus, HNE is known also as “second messenger of
free radicals", as it lives longer than free radicals and can migrate
within the cell gaining biological activities that resemble free radicals.
Additionally, HNE is able to bind to macromolecules and thereby
modify their function even if not being toxic [15,16]. The effects of
HNE are ranging from cell growth regulation, intracellular signal
transmission and communication with the cellular environment even-
tually leading to cytotoxicity and cell death, which mainly depend on
concentrations of HNE, the character of the biomolecules involved and
the type of cells affected by HNE [17–21]. In various malignant cells
ROS levels are permanently elevated due to the malignant cell
transformation and increased metabolism, whereas their antioxidant
levels are often decreased [22–24]. Although such unfavorable condi-
tions should normally lead to apoptosis and cell death, instead
uncontrolled tumor cell proliferation occurs, while the tumor-specific
antioxidant protection system neutralizes the high ROS levels. A
possible cause could be an alternative antioxidant protection route by
the multispecific transport protein Ral-binding protein1 (RALBP1) and
its conjugation potential with the HNE molecule [25], as well as the
increased activity of transcription factor nuclear factor erythroid 2-
related factor 2 (Nrf2) responsible for antioxidant synthesis within the
cell. Increased Nrf2 activity has been noted in malignant lung tumor
cells, and is in correlation with chemoresistance and radioresistance of
tumors. Increased Nrf2 activity in malignant cells is the result of a
mutation in the cytoplasmic molecule Keap1 (Kelch-like ECH-asso-
ciated protein 1), which in conjunction with Nrf2 causes its inactivation
[26–28]. Hence, the multipotent role of the HNE molecule is demon-
strated by its potential to create a HNE-Keap1 complex [29], as well as
the HNE-His type of protein adducts, thereby directly affecting the
tumor antioxidant protection system, but also causing inflammation
[30].
The association between chronic inflammation and tumors has
been proven repeatedly in numerous experimental and epidemiological
studies. An important feature of tumors is their potential for chemo-
taxis and inflammatory cell activation [31]. The role of tumor-
associated macrophages (TAM) has been thoroughly researched. The
activated macrophages show an increased expression of the enzyme
group nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
(Nox) and inducible nitric oxide synthase (iNOS). They stimulate
tumor invasion by releasing the matrix metalloproteinases MMP-2
and MMP-9, which break down the extracellular matrix and basal
membrane [32]. TAMs also stimulate tumor angiogenesis by releasing
vascular endothelial growth factor (VEGF) and endothelin-2 urokinase-
type plasminogen activator [33,34]. The host-to-tumor relationship can
therefore be manifested by increased accumulation of inflammatory
cells in the vicinity of the tumor and the release of ROS and second
messengers of oxidative stress, such as HNE molecules, which have the
potential to affect the signaling pathways in cancer cells [35,36].
By comparing the metabolic activity of the tumor in different PET/
CT scans with the immunohistochemistry findings of HNE in the
malignant cells, tumor stroma and in normal tissue adjacent to the
tumor, the aim of this research was to determine whether the tumor
affects the surrounding tissue by the spread of oxidative stress or
whether the surrounding tissue aims to affect the tumor as a reflection
of the host reaction, by way of an inflammatory reaction and HNE
generated within malignant tissue and in the surrounding non-
malignant tissue.
2. Patients, materials and methods
2.1. Patients
Nineteen patients (52.8%) with primary lung tumors and 17
patients (47.2%) with secondary lung tumors were involved in this
study.
In the group of patients with primary lung tumors majority suffered
from adenocarcinoma, followed by planocellular carcinoma, non-small
cell lung cancer (NSCLC), and carcinoid, while one patient was
diagnosed with mesothelioma. Two out of three patients were current
or former smokers, while every third patient received platinum-based
chemotherapy prior to lung resection (Table 1).
In the group with secondary lung tumors, 13 patients had been
pathohistologically diagnosed with metastatic adenocarcinoma of the
rectosigmoid colon. The other diagnoses included metastatic breast,
kidney, and laryngeal cancer. Every third patient was current or former
smoker, while most of them had undergone chemotherapy prior to lung
resection. The mean time from the last chemotherapy cycle to resection
was 18.8 months (Table 2).
The tissue samples for pathohistological analysis were obtained
after lung lobectomy or segmentectomy performed at the Department
of Thoracic Surgery of the Clinical Hospital Dubrava in Zagreb. The
most frequently used surgical technique was video-assisted thoraco-
scopic surgery (VATS), and in several patients thoracotomy was
necessary due to the extent of the procedure. The indication for open
biopsy of the tumor growth was established by the thoracic surgeon and
the attending pulmonologist. The basic requirement for enrollment
into this prospective study were positive PET-CT scans of pulmonary
Fig. 1. PET-CT scan of solitary malignant pulmonary nodule reflecting cancer growth as
shining spot (SUVmax 5.0).
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nodules of different size and different SUVmax value. The qualitative
and quantitative PET-CT results were assessed by physicians from the
Clinical Hospital Center Zagreb and the Medical Center Medikol
Zagreb in accordance with the standardized diagnostic protocol.
2.2. Pathohistological and immunohistochemical analysis
Tissue sample collection was performed by pathologists at the
Clinical Hospital Dubrava, as well as the further pathohistological and
immunohistochemical analysis necessary to establish the pathohisto-
logical diagnosis. Three samples were collected from each patient; one
from the tumor itself, one from the tumor and the adjacent tissue, and
one from the surrounding tissue up to 10 mm from the tumor.
Immediately upon resection, the samples were fixed in 10% formalin,
dehydrated with ethanol, and embedded into a paraffin blocks. The
paraffin blocks were then cut into 5μ thin slices, deparaffinized and
rehydrated. One slice from each sample was stained with hematoxylin-
eosin and analyzed by the attending pathologist from the Clinical
Hospital Dubrava, while another slice from each sample was addition-
ally prepared for immunohistochemical analysis with monoclonal
antibodies (mAb) for HNE-histidine conjugate applied at a dilution
of 1:10 in LabOS (Rudjer Boskovic Institute, Zagreb). This genuine
monoclonal antibody, specific for the HNE-histidine adducts was
prepared at the University of Graz from the culture medium of the
clone derived from a fusion of Sp2-Ag8 myeloma cells with B-cells of a
BALBc mouse immunized by HNE-modified keyhole limpet hemocya-
nine. For the immunohistochemical detection of the HNE-protein
adducts the immunoperoxidase technique was used with secondary
rabbit-anti-mouse antibodies (EnVision kit, DAKO, Glostrup,
Denmark). Finally, the sections were incubated with diaminobenzidine
(DAB, Dako Glostrup, Denmark) substrate, and counterstained with
haematoxylin (Kemika, Zagreb, Croatia) as described before [18]. The
immunohistochemical slides prepared in this way were re-analyzed by
a second pathologist at the Clinical Hospital Center Zagreb, not
knowing the previous allocation of the patients to respective study
groups.
This research was approved by the Ethical Committee of the Clinical
Hospital Dubrava, and informed consent was obtained from each
patient prior to the surgical procedure, allowing additional testing of
the tissue samples for HNE monoclonal antibodies at the Rudjer
Boskovic Institute, Zagreb, as described before.
The HNE immunohistochemical positivity was determined by the
usual semi-quantitative method [37], and the samples were marked in
the following way:
- negative sample (0), +/- very low, hardly discernible positivity
(0.5), + weakly positive (1),
++ moderately positive (2), +++ very positive sample (3).
2.3. Statistical analysis
The obtained results were analyzed by MedCalc using the following
statistical methods: Fisher test, Chi-squared test, Pearson correlation
and Mann-Whitney test. For the statistical purposes the observed
variables were grouped into two categories: 0, 0.5, and 1 (weakly
positive - group 1) and 2 and 3 (definitely positive - group 2). Statistical
significance was established at p < 0.05.
3. Results
No statistically significant difference was established between HNE-
intensity in the cytoplasm of tumor cells that were exposed to
neoadjuvant chemotherapy when compared to those who were not
treated by chemotherapy. The mean time from the last chemotherapy
cycle to resection was 5 months. Chemotherapy also did not affect the
HNE-immunopositivity in non-malignant tissue surrounding respec-
tive cancer (Tables 1, 2).
The mean tumor volume of 2.87 cm3 of the secondary tumors was
significantly (p < 0.01) smaller than was the mean size of primary lung
cancer of 17.56 cm3. However, comparison of intensity of metabolic
tumor activity (SUV) in respect to the tumor size between primary and
secondary tumors did not show statistically significant difference in
their respective SUV intensities. There was also no statistically
significant difference between HNE-immunohistochemical intensity
in the malignant cells of primary and of the secondary lung neoplasms.
The predominant value of the HNE intensity in the cytoplasm of
primary and of secondary lung tumor cells was ++(2) being the most
pronounced in necrotic regions.
In the tumor stroma HNE-immunohistochemical intensities were
only moderate, graded either as +/-(0.5), and +(1) or even negative,
while the predominant intensity was 0.5 (+/-). There was no statisti-
cally significant difference in the HNE-intensity of inflammatory cells
of the tumor stroma in either primary or secondary lung tumors.
Among the inflammatory cells, macrophages (TAM) were predominant,
along with a very small number of neutrophils, fibroblasts and
lymphocytes.
However, a statistically significant difference was obtained when
the HNE intensities of surrounding lung tissue was compared between
primary and secondary lung tumors (p < 0.001). In the group of
primary lung tumors, a weakly positive HNE intensity of +(1) was
predominant, while in the surrounding tissue of secondary lung tumors
higher HNE intensities of ++(2) and +++(3) were most frequently
found. No HNE-negative surroundings were recorded at all (Fig. 2).
A statistically significant difference (p=0.02) between primary and
secondary lung tumors was also observed for the HNE intensities of the
edematous fluid in the cancer surroundings. The inflammatory cells in
the vicinity of secondary tumors also gave significantly (p < 0.001)
higher levels of HNE than was observed for the inflammatory cells in
the vicinity of primary tumors.
Finally, the HNE-immunohistochemical intensity of the surround-
ings of primary and of secondary lung tumors and tumor volumes were
compared, showing a statistically significant (r=−0.43, p < 0.05) nega-
tive correlation between the volume of secondary lung cancer (metas-
tasis) and the HNE-immunopositivity in surrounding lung tissue,
which was not observed in case of primary lung cancer.
4. Discussion
The mean tumor volume of the secondary, metastatic tumors was
significantly smaller than was the mean primary lung tumor volume
prior to resection, probably due to the fact that the patients with
metastatic cancer had been actively followed by imaging methods to
monitor the onset of metastasis of their primary tumor. However,
comparison of the intensity of tumor metabolic activity (SUV) and
tumor size did not show statistically significant differences between the
SUV intensities of primary and of secondary lung tumors. These
findings confirm the known fact that at the time of establishing the
diagnosis primary lung tumor cells are characterized by anaerobic
glycolysis, while SUV intensity mainly depends on the number of
metabolically active cells. These results are also confirmed by the fact
that there was no statistically significant difference between the HNE
intensities in the cytoplasm of primary and of secondary lung tumor
cells.
The neoadjuvant chemotherapy used did not influence the appear-
ance of HNE in tumors or in surrounding lungs, which is likely due to
the choice of chemotherapeutic protocols as well as the period from the
last cycle to lung resection (the mean time for primary tumors was 5
months, and for secondary tumors 18.8 months.
The observed correlation of the intensity of occurrence of HNE-
protein conjugates in the cells with the tumor volume indicates a
mutual dependence of lipid peroxidation and tumor size, which was not
described before. Although one may assume that these findings suggest
that lipid peroxidation enhances the tumor growth, at least because
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HNE is known growth factor [16,38], we think it is actually the other
way around. Namely, HNE can indeed, at least in vitro, enhance the
growth of different types of cells, but only if present at very low levels
that cannot be determined by immunocytochemistry or immunohis-
tochemistry [39]. If present at higher concentrations that can be
immunochemically visualized in cells and tissues, HNE exerts proa-
poptotic effects proportional to the level of the HNE-protein adducts
[40] and can even suppress the growth of malignant stem cells by
interaction with oxidatively modified extracellular matrix. Eventually,
at very high concentrations, HNE can also induce tumor necrosis.
While in the initial stages of carcinogenesis malignant cells could
resemble their normal counterparts and under aggressive oxidative
stress manifested by increase of HNE production behave individually
[41], in advanced stages the altered metabolism of cancer could lead to
more uniform behavior of malignant cells. Because malignant cells
have less expressed capacities of antioxidants, such as glutathione [24]
and consequently use alternative, tumor-specific antioxidant mechan-
ism to defend themselves from toxicity of oxidative stress by tumor-
specific membrane associated catalase [30], which is suppressed by
HNE, malignant cells are more sensitive to cytotoxicity of HNE than
are non-malignant, normal cells.
Therefore, tumor progression associated with enhanced lipid
peroxidation could cause the tumor decay through apoptosis or even
necrosis, as was recently proposed to represent the particular mechan-
ism of the host defense against invading cancer [30,42]. This possibility
was recently confirmed also by findings of abundant HNE present in
the most necrotic regions of the lung cancer, which were also associated
to systemic disturbance in lipid metabolism and generalized enhance-
ment of the HNE production [43].
Hence, non-malignant cells in the tumor surroundings could
enhance the intensity of lipid peroxidation to defend themselves from
invading cancer jointly with the immuno-competent inflammatory
cells. Among the inflammatory cells in the tumor stroma, macrophages
(TAM) were revealed to dominate, along with a very small number of
neutrophils, fibroblasts, and lymphocytes. However, there was no
statistically significant difference found in HNE intensities in the
inflammatory cells of the tumor stroma between primary and second-
ary lung tumors, while their predominant value of HNE intensity in the
inflammatory cells of the tumor stroma of primary and secondary lung
tumors was +/- (0.5). The occurrence of only so small amounts of
oxidative stress products within tumor stroma and stromal inflamma-
tory cells confirms the known fact that inflammatory cells in the tumor
stroma are not directed against the tumor, but rather serve its function.
Opposite to that, significant difference was obtained between the
HNE intensities of the surroundings of primary and of secondary lung
tumors. These findings support the hypothesis that host defense
against cancer may be explained by an increased activity of inflamma-
tory cells in the surroundings of secondary lung tumors and a
subsequent increased ROS/RNS synthesis. This can further lead to a
locally increased permeability of the alveo-capillary membrane due to
the effect on the endothelial and epithelial cells and enhanced produc-
tion of HNE in non-malignant cells in the vicinity of cancer, thus
causing decay of invading cancer as was shown already in the rat model
of spontaneously regressing W256 carcinoma [35,36].
Comparison of the HNE intensity of the surroundings of primary
and secondary lung tumors with SUV intensity and HNE intensity of
the tumor cells did not reveal statistically significant differences. Thus,
HNE-mediated oxidative stress in the non-malignant tissue surround-
ing cancer was not caused by the tumor invasion but by the reaction of
the normal cells to cancer aggression, in particular by defense
generated through inflammatory process. Namely, the intensity of lipid
peroxidation determined by the HNE immunopositivity of surrounding
tissues was negatively correlated with the volume of secondary, but not
of primary tumors, which means that there is a significant difference in
the behavior of primary and secondary tumors with regard to the
development of lipid peroxidation in the surrounding tissue. The
occurrence of higher levels of HNE-protein conjugates in the vicinity
of smaller secondary tumors could mean that HNE is generated by
non-malignant cells to act as an obstacle to the growth of metastatic
tumors.
In conclusion we may state that both PET-CT and HNE immuno-
histochemistry reflect cancer development related to the size of the
malignant tissue, while non-malignant lung tissue in the vicinity of
cancer expresses more pronounced lipid peroxidation in metastatic
than in primary malignancies tending to defend itself from cancer, as
was recently revealed in case of human liver cancer [44].
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